The 33 references in paper Editorial article , статья Редакционная (2014) “Сочетание хронической обструктивной болезни легких и бронхиальной астмы: согласительный документ Испанского общества пульмонологов и торакальных хирургов // Chronic obstructive pulmonary disease associated with asthma. Consensus document of Spanish Society of Pulmonologists and Thoracic Surgeons (SEPAR)” / spz:neicon:pulmonology:y:2013:i:1:p:13

1
Peces2Barba G., Barbera J.A., Agusti A. et al.Guia Clinica SEPAR$ALAT de diagnostico y tratamiento de la EPOC. Arch. Bronconeumol. 2008; 44: 271–281.
(check this in PDF content)
2
GEMA 2009. Guia Espanola para el Manejo del Asma. Madrid: Luzan; 2009.
(check this in PDF content)
3
Gibson P.G., Simpson J.L. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64: 728–735.
(check this in PDF content)
4
Tashkin D.P., Celli B., Decramer M. et al. Bronchodila$tor responsiveness in patients with COPD. Eur. Respir. J. 2008; 31: 742–750.
(check this in PDF content)
5
Siva R., Green R.H., Brightling C.E. et al. Eosinophilic air$ way inflammation and exacerbations of COPD: a ran$ domised controlled trial. Eur. Respir. J. 2007; 29: 906–913.
(check this in PDF content)
6
Miravitlles M. Tratamiento individualizado de la EPOC: una propuesta de cam$bio. Arch. Bronconeumol. 2009; 45 (Suppl. 5): 27–34.
(check this in PDF content)
7
Miravitlles M., Calle M., Soler2Catalun~a J.J.Fenotipos clin$ icos de la EPOC. Iden$tificacion, definicion e implica$ ciones para las guias de tratamiento. Arch. Bronconeumol. 2011, doi:10.1016/j.arbres.2011.10.007.
(check this in PDF content)
8
Herland K., Akselsen J.P., Skjonsberg O.H., Bjermer L.How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir. Med. 2005; 99: 11–19.
(check this in PDF content)
9
Petty T.L. The history of COPD. Int. J. Chron. Obstruct. Pulm. Dis. 2006; 1: 3–14.
(check this in PDF content)
10
UNICEF. Visualisation in participatory programmes. A ma$ nual for facilitators and trainers involved in participatory group events. Bangladesh; 1993 [accessed 2011]. Available from: http://portals.wi. wur.nl/files/docs/ppme/ VIPP_Unicef.pdf
(check this in PDF content)
11
Kaner S., Lind L., Toldi C.A facilitator's guide to participa$ tory decision making. USA: John Wiley & Sons / Jossey$ Bass; 2007.
(check this in PDF content)
12
Burrows B., Bloom J.W., Traver G.A., Cline M.G. The course and prognosis of different forms of chronic airways obstruc$ tion in a sample from the general population. N. Engl. J. Med. 1987; 317: 1309–1314.
(check this in PDF content)
13
Orie N.G.M., Sluiter H.J., De Vries K. et al.The host factor in bronchitis. In: Orie N.G.M., Sluiter H.J., eds. Bronchitis. Assen, Netherlands: Royal Van Gorcum; 1961. 43–59.
(check this in PDF content)
14
Tinkelman D.G., Price D.B., Nordyke R.J. et al. Symptom$ based questionnaire for differentiating COPD and asthma. Respiration 2006; 73: 296–305.
(check this in PDF content)
15
Leigh R., Pizzichini M.M., Morris M.M. et al.Stable COPD: predicting benefit from high$dose inhaled corticosteroid treatment. Eur. Respir. J. 2006; 27: 964–971.
(check this in PDF content)
16
Williamson P.A., Menzies D., Clearie K.L. et al. Dose$ response for inhaled fluticasone on airway and systemic inflammation in COPD. Eur. Respir. J. 2011; 37: 206–209.
(check this in PDF content)
17
Welte T., Miravitlles M., Hernandez P. et al. Efficacy and tol$ erability of budesonide / formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180: 741–750.
(check this in PDF content)
18
Valk P., Monninkhof E., van der Palen J. et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am. J. Respir. Crit. Care Med. 2002; 166: 1358–1363.
(check this in PDF content)
19
Wouters E.F., Postma D.S., Fokkens B. et al., COSMIC (COPD, Seretide: a Multi$Center Intervention, Characteri$ zation) Study Group. Withdrawal of fluticasone propionate from combined salmeterol / fluticasone treatment in patients with COPD causes immediate and sustained dis$ ease deterioration: a randomised controlled trial. Thorax
(check this in PDF content)
20
5; 60: 480–487. 20.Cosio B.G., Fiorentino F., Scrimini S. EPOC y asma. Arch. Bronconeumol. 2010; 46 (Suppl. 8): 2–7.
(check this in PDF content)
21
Brindicci C., Ito K., Resta O. et al. Exhaled nitric oxide from lung periphery is increased in COPD. Eur. Respir. J. 2005; 26: 52–59.
(check this in PDF content)
22
Rutgers S.R., van der Mark T.W., Coers W. et al. Markers of nitric oxide metabolism in sputum and exhaled air are not increased in chronic obstructive pulmonary disease. Thorax 1999; 54: 566–580.
(check this in PDF content)
23
Papi A., Romagnoli M., Baraldo S. et al.Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 162: 1773–1777.
(check this in PDF content)
24
Lehtimaki L., Kankaanranta H., Saarelainen S. et al. Bron$ chial nitric oxide is related to symptom relief during flutica$ sone treatment in COPD. Eur. Respir. J. 2010; 35: 72–78.
(check this in PDF content)
25
Singh S., Amin A.V., Loke Y.K. Long$term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta$analysis. Arch. Intern. Med. 2009; 169: 219–229.
(check this in PDF content)
26
Nelson H.S., Weiss S.T., Bleecker E.R. et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129: 15–26.
(check this in PDF content)
27
Barnes P.J. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc. Am. Thorac. Soc. 2005; 2: 334–339.
(check this in PDF content)
28
Han M.K., Agusti A., Calverley P.M. et al.Chronic obstruc$ tive pulmonary disease phenotypes. The future of COPD. Am. J. Respir. Crit. Care Med. 2010; 182: 598–604.
(check this in PDF content)
29
Hardin M., Silverman E.K., Barr R.G. et al.The clinical fea$ tures of the overlap between COPD and asthma. Respir. Res. 2011; 12: 127; doi: 10.1186/1465$9921$12$127.
(check this in PDF content)
30
Hospers J.J., Postma D.S., Rijcken B. et al. Histamine airway hyper$responsiveness and mortality from chronic obstruc$ tive pulmonary disease: a cohort study. Lancet 2000; 356: 1313–1317.
(check this in PDF content)
31
Vestbo J., Edwards L.D., Scanlon P.D. et al.Changes in forced expiratory volume in 1 second over time in COPD. N. Engl. J. Med. 2011; 365: 1184–1192.
(check this in PDF content)
32
Grupo de trabajo de GESEPOC. Hacia un nuevo enfoque en el tratamiento de la EPOC. Guia Espahola de la EPOC (GESEPOC). Arch. Bronconeumol. 2011; 47: 379–381.
(check this in PDF content)
33
Nadeem N.J., Taylor S.J., Eldridge S.M.Withdrawal of inhaled corticosteroids in individuals with COPD – a sys$ tematic review and comment on trial methodology. Respir. Res. 2011; 12: 107. Поступила 14.03.13
(check this in PDF content)